Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors.

RATIONALE AND OBJECTIVES Hybrid single photon-emission computed tomographic (SPECT) and computed tomographic (CT) imaging for the investigation of neuroendocrine tumors allows the fusion of functional and anatomic information in a rapid and efficient method. The aim of this study was to assess the incremental diagnostic value of (111)In pentetreotide SPECT/CT imaging compared with traditional planar and SPECT imaging with respect to lesion localization and characterization and reader confidence. MATERIALS AND METHODS Forty-nine patients (23 male, 26 female; mean age, 56.9 years; range, 14-88 years) who underwent (111)In pentetreotide planar, SPECT, and SPECT/CT imaging were eligible for this retrospective study, including patients with suspected or confirmed carcinoid tumors (n = 24), endocrine pancreatic tumors (n = 18), medullary thyroid cancer (n = 3), paragangliomas (n = 2), and multiple endocrine neoplasia type I (n = 2). Planar and SPECT images were reviewed by two blinded readers, followed by interpretation using additional SPECT/CT images in a subsequent session. A third reader provided consensus in cases with disagreements. RESULTS In 55 of 89 lesions (61.8%), (111)In pentetreotide SPECT/CT imaging improved lesion localization compared to planar and SPECT imaging; in 25 of 89 lesions (28.1%), SPECT/CT imaging changed lesion classification. In 20 of 49 patients (40.8%) for reader 1 and 14 of 49 patients (28.6%) for reader 2, (111)In pentetreotide SPECT/CT imaging provided incremental diagnostic value, which was considered likely to affect patient management in twelve of 20 and seven of 14 patients, respectively. Increased reader confidence was found in 32 of 49 patients (65.3%) for both readers with uniformly high confidence after SPECT/CT interpretation. CONCLUSIONS Hybrid (111)In pentetreotide SPECT/CT imaging provides incremental diagnostic value and greater reader confidence over planar and SPECT imaging. This is achieved though superior lesion localization, the identification of physiologic activity, and additional anatomic information derived from the nondiagnostic CT portion of the study.

[1]  Holger Amthauer,et al.  Influence of attenuation correction by integrated low-dose CT on somatostatin receptor SPECT , 2007, Nuclear medicine communications.

[2]  R. Bale,et al.  Image fusion analysis of 99mTc-HYNIC-Tyr3-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  R. Felix,et al.  Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumours , 2005, European Radiology.

[4]  E. P. Krenning,et al.  Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients , 1993, European Journal of Nuclear Medicine.

[5]  A. Engel,et al.  SPECT/CT hybrid imaging with 111In‐pentetreotide in assessment of neuroendocrine tumours , 2003, Clinical endocrinology.

[6]  E P Krenning,et al.  Neuroendocrine tumors and somatostatin: imaging techniques. , 2005, Journal of endocrinological investigation.

[7]  Frank P DiFilippo,et al.  SPECT/CT imaging: clinical utility of an emerging technology. , 2008, Radiographics : a review publication of the Radiological Society of North America, Inc.

[8]  A. Moreira,et al.  Value of SPET/CT image fusion in the assessment of neuroendocrine tumours with 111In-pentetreotide scintigraphy. , 2005, Revista espanola de medicina nuclear.

[9]  A. Engel,et al.  The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  Christopher J. Taylor,et al.  The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours , 2006 .

[11]  C. Claussen,et al.  Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  P. Erba,et al.  Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. , 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[13]  Nirav P. Shah,et al.  Endocrine Neoplasm Scintigraphy: Added Value of Fusing SPECT/CT Images Compared With Traditional Side-by-Side Analysis , 2006, Clinical nuclear medicine.

[14]  Richard P Baum,et al.  Imaging of neuroendocrine tumors. , 2006, Seminars in nuclear medicine.